News

A new study entitled “HSF-1–mediated cytoskeletal integrity determines thermotolerance and life span” published in Science unravels the role of heat shock transcription factor–1 (HSF-1) in aging and associated neurodegenerative diseases, such as Alzheimer’s. Heat shock proteins (HSP) are a group of proteins induced by heat…

A new review article entitled “Why industry propaganda and political interference cannot disguise the inevitable role played by human exposure to aluminum in neurodegenerative diseases, including Alzheimer’s disease,” published in Frontiers in Neurology, argues the role of aluminum in the development of Alzheimer’s disease. The study author,…

A pioneering in vitro culture model of Alzheimer’s disease was established for the first time by researchers from the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH), entitled “A three-dimensional human neural cell culture model of Alzheimer’s disease.” The study, which was recently published in the …

People living in regions with deprived, disadvantaged conditions have higher probabilities of suffering cognitive dysfunctions than those living in regions with more developed living conditions, according to a study from the University of Ulster in United Kingdom, led by Professor Helene McNulty. The results of the research based on Ireland data revealed…

Difficult decisions facing Alzheimer’s and other advanced dementia patients must be made with careful consideration for the health and well-being of patients and their caregivers. A report in Nutrition in Clinical Practice, entitled, “Gastrostomy Tube Placement in Patients With Advanced Dementia or Near End…

The Alzheimer’s Association recently awarded Jose Abisambra, assistant professor at the University of Kentucky and researcher at the Sanders-Brown Center on Aging, a $100,000 New Investigator Research Grant to fund his work into understanding the function of a brain protein that alters during the development of Alzheimer’s disease. The…

Amarantus BioScience Holdings, Inc. recently released promising results from the Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic for Alzheimer’s disease (AD) LP-002 study. Amarantus is a biotechnology company focused on research and development of treatments and diagnostics for diseases related to neurodegenerative and apoptosis (programmed cell death) processes that contribute…

Muses Labs, based at Research Triangle Park in Raleigh, North Carolina, creates software-based systems to enable personalized therapy for the treatment of complex diseases. The company recently announced the development of its first offering for addressing Alzheimer’s disease. The combination therapy it implements is based on a broad understanding…

New diagnostics are currently being developed by researchers to help doctors ascertain risk factors for Alzheimer’s Disease before the onset of symptoms. A recent study showed that a brain scan lasting no longer than 5 minutes could potentially yield results indicative of dementia risk by determining…

Avanir Pharmaceuticals, Inc. will present their most-recent results from two clinical trials currently underway for treating conditions associated with Alzheimer’s disease (AD). The data is set to be presented at the American Neurological Association’s (ANA) Annual Meeting in Baltimore, Maryland, from October 12-14, 2014. The phase II clinical trial evaluated…